| Name | Title | Contact Details |
|---|
When it comes to the world of automotive components, JVIS has continued to be the supplier of choice for leading global brands. Why? Were fast. Were flexible. Were everywhere. With our extensive art-to-part capabilities, we can do whatever it takes to help our customers get the solution they need. And facilities around the world and an international network of dedicated partners — we can provide global services with localized support you cant get from other suppliers. Thats great news for both your production line and bottom line. Whether you need a sleek new exterior part or a complete interior solution that creates a more comfortable ride, our team of experts can quickly design, produce and deliver exactly what you need.
27North Inc. is a luxury expedition vehicle manufacturer, providing durable and luxurious vehicles tailored to suit adventure seekers, leisurely travelers, and mobile lifestyle enthusiasts. Since 2017, our team has provided our clients with the highest quality, first-class service. With our comprehensive offerings, you can expect to receive superior customer service from the initial contact and beyond.
FM Global is a Rhode Island-based insurance company that specializes in property insurance, risk consulting and loss prevention for businesses.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.